論文

国際誌
2018年2月

Definitive chemoradiotherapy with low-dose continuous 5-fluorouracil reduces hematological toxicity without compromising survival in esophageal squamous cell carcinoma patients.

Clinical and translational radiation oncology
  • Hirotake Saito
  • ,
  • Atsushi Ohta
  • ,
  • Eisuke Abe
  • ,
  • Motoki Kaidu
  • ,
  • Miki Shioi
  • ,
  • Toshimichi Nakano
  • ,
  • Tomoya Oshikane
  • ,
  • Kensuke Tanaka
  • ,
  • Katsuya Maruyama
  • ,
  • Naotaka Kushima
  • ,
  • Satoshi Tanabe
  • ,
  • Satoru Utsunomiya
  • ,
  • Ryuta Sasamoto
  • ,
  • Hidefumi Aoyama

9
開始ページ
12
終了ページ
17
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.ctro.2017.12.003

Background and purpose: To compare chemoradiotherapy (CRT) with low-dose continuous 5-fluorouracil (5FU) to CRT with 5FU+cisplatin (CDDP) for esophageal squamous cell carcinoma (ESCC) in a retrospective cohort study. Methods and materials: We reviewed the cases of Stage I-IV ESCC patients who underwent definitive CRT in 2000-2014. Concomitant chemotherapy was one of the three regimens: (1) high-dose intermittent 5FU and CDDP (standard-dose FP: SDFP), (2) low-dose continuous 5FU and CDDP (LDFP), or (3) low-dose continuous 5FU (LD5FU). The general selection criteria for chemotherapy were: SDFP for patients aged <70 yrs; LDFP for those aged 70-74 yrs; LD5FU for those aged ≥75 yrs or with performance status (PS) ≥3. Propensity scores were derived with chemotherapy (LD5FU vs. 5FU+CDDP) as the dependent variable. Results: In a multivariate analysis, chemotherapy (LD5FU vs. SDFP, p = .24; LDFP vs. SDFP, p = .52) did not affect the overall survival (OS). LD5FU caused significantly less grade 3-4 leukopenia (9%) compared to SDFP (47%) and LDFP (44%) (p < .001). In a propensity-matched analysis, LD5FU affected neither OS (HR 1.06; 95%CI 0.55-2.05; p = .87) nor progression-free survival (HR 0.95, 95%CI 0.50-1.81; p = .87). Conclusion: CRT with low-dose continuous 5FU may be a less toxic option for elderly ESCC patients.

リンク情報
DOI
https://doi.org/10.1016/j.ctro.2017.12.003
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/29594245
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862669
ID情報
  • DOI : 10.1016/j.ctro.2017.12.003
  • PubMed ID : 29594245
  • PubMed Central 記事ID : PMC5862669

エクスポート
BibTeX RIS